The White House announced that TrumpRx and a most-favored-nation pricing approach will start in January 2026, following agreements the administration says link U.S. drug prices to lower foreign prices and direct-to-consumer discounts first disclosed in late September 2025.Those agreements, which the administration cites with companies including Pfizer, AstraZeneca, EMD Serono, Novo Nordisk and Eli Lilly, claim steep cuts on drugs such as Eucrisa, Xeljanz, Zavzpret, GLP-1 medications and insulin, but experts say many figures appear implausible, could be typographical errors and that legal and logistical hurdles make immediate nationwide availability unlikely.